Allspring Global Investments Holdings LLC Has $353.75 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Allspring Global Investments Holdings LLC increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 29.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,291,126 shares of the medical research company’s stock after buying an additional 516,521 shares during the quarter. Charles River Laboratories International comprises about 0.6% of Allspring Global Investments Holdings LLC’s portfolio, making the stock its 27th biggest position. Allspring Global Investments Holdings LLC’s holdings in Charles River Laboratories International were worth $353,750,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in Charles River Laboratories International by 5.1% during the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock worth $644,980,000 after buying an additional 208,586 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its stake in Charles River Laboratories International by 8.0% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock worth $293,555,000 after buying an additional 144,732 shares during the period. Invesco Ltd. raised its stake in Charles River Laboratories International by 7.2% during the 1st quarter. Invesco Ltd. now owns 1,108,358 shares of the medical research company’s stock worth $166,830,000 after buying an additional 74,178 shares during the period. Ariel Investments LLC raised its stake in Charles River Laboratories International by 3.1% during the 1st quarter. Ariel Investments LLC now owns 1,100,776 shares of the medical research company’s stock worth $165,689,000 after buying an additional 33,449 shares during the period. Finally, Earnest Partners LLC raised its stake in Charles River Laboratories International by 2.3% during the 1st quarter. Earnest Partners LLC now owns 1,004,607 shares of the medical research company’s stock worth $151,213,000 after buying an additional 22,453 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the transaction, the executive vice president directly owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on CRL. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Wall Street Zen lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 7th. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, October 3rd. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Finally, Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Eight equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $179.93.

Charles River Laboratories International Stock Performance

CRL stock opened at $167.17 on Monday. The firm has a market cap of $8.23 billion, a PE ratio of -125.69, a P/E/G ratio of 4.47 and a beta of 1.50. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average of $159.23 and a 200-day moving average of $147.48. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).